Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Sharon Lu"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 1, Pp 87-94 (2023)
Abstract Dostarlimab (JEMPERLI) is an anti‐programmed cell death protein‐1 (PD‐1) monoclonal antibody (mAb) which is approved by the US Food and Drug Administration for patients with recurrent/advanced mismatch repair‐deficient solid tumors,
Externí odkaz:
https://doaj.org/article/808cae7bbeba4b96a956357928b9671a
Autor:
Marilyn Patterson, Lee Anne Beausang, Bonita Rup, Ronald R. Bowsher, Kim Krug, Murad Melhem, Sharon Lu
Publikováno v:
AAPS Open, Vol 7, Iss 1, Pp 1-16 (2021)
Abstract Dostarlimab (JEMPERLI) is a humanized anti-programmed death 1 (PD-1) immunoglobulin (Ig)G4-kappa monoclonal antibody that binds to the PD-1 receptor and competitively inhibits binding of its ligands, PD-L1 and PD-L2. Dostarlimab was recently
Externí odkaz:
https://doaj.org/article/70ba25086cdd4d4b9702c4e73dd8a05e
Publikováno v:
AAPS Open, Vol 7, Iss 1, Pp 1-14 (2021)
Abstract Dostarlimab is a humanized anti–PD-1 monoclonal antibody. Dostarlimab (JEMPERLI; TSR-042) was recently approved in the USA and in the EU. The presence of neutralizing antibodies (NAbs) is a cause for concern because they block the therapeu
Externí odkaz:
https://doaj.org/article/9cc562b825a24dee8a7fce5d389aa00c
Autor:
Wei Guo, Manish R Patel, Nashat Gabrail, Jordi Rodon, Erika Hamilton, Timothy A Yap, Meghan Duncan, Alberto Bessudo, Jasgit Sachdev, Lena Evilevitch, Sujatha Kumar, Sharon Lu, Bruce J Dezube
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and associated with improved antitum
Externí odkaz:
https://doaj.org/article/e29828d5a2dc440fb2aab02626d02441
Autor:
Sujatha Kumar, Srimoyee Ghosh, Geeta Sharma, Zebin Wang, Marilyn R. Kehry, Margaret H. Marino, Tamlyn Y. Neben, Sharon Lu, Shouqi Luo, Simon Roberts, Sridhar Ramaswamy, Hadi Danaee, David Jenkins
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the treatment landscape for patients with cancer. Clinical activity of anti-PD-(L)1 antibodies has resulted in increased median overall survival and
Externí odkaz:
https://doaj.org/article/9da6bd9d6003443393ec5b573b0b1c81
Autor:
Victor E. Chen, BS, Erin F. Gillespie, MD, Kaveh Zakeri, MD, James D. Murphy, MD, Catheryn M. Yashar, MD, Sharon Lu, MD, John P. Einck, MD
Publikováno v:
Advances in Radiation Oncology, Vol 2, Iss 2, Pp 105-109 (2017)
Purpose: Our goal was to determine the impact of pathologic response after neoadjuvant chemotherapy in triple negative breast cancer (TNBC) on the subsequent risk of locoregional recurrence (LRR) and disease-free survival (DFS) in the setting of adju
Externí odkaz:
https://doaj.org/article/adbcae98f1e74e0cbec34c3143412d62
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 12:87-94
Dostarlimab (JEMPERLI) is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody (mAb) which is approved by the US Food and Drug Administration for patients with recurrent/advanced mismatch repair-deficient solid tumors, including endomet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f408331fffb8385f4b09c3d5016ae4d
https://doi.org/10.1002/psp4.12878
https://doi.org/10.1002/psp4.12878
Publikováno v:
British Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9d1330f61d33450faae4f0aa5cb82ef
https://doi.org/10.1111/bcp.15700
https://doi.org/10.1111/bcp.15700
Autor:
Drew W. Rasco, Amita Patnaik, Kristen McEachern, Sharon Lu, Wei Guo, Lisa Blaydorn, Murali Beeram, Ellie Im, Amy Mirabella, Jasgit C. Sachdev, Hadi Danaee, Glen J. Weiss
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-1) have improved patient outcomes in a broad range of cancers. The objective of this analysis was to evaluate the PK, pharmacodynamics (PDy), and safety of dostarlim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a01bdcc28b555d4d52481b0db48989cc
http://europepmc.org/articles/PMC8739161
http://europepmc.org/articles/PMC8739161
